Cloudbreak Pharma Inc. (SEHK: 2592)
Health Care · Biotechnology · US
HK$—
— today · — 1Y
Cloudbreak Pharma Inc. (SEHK: 2592) operates in the Biotechnology industry within the Health Care sector. The company is valued at $140.32M and employs 61 people.
trading between 0.90 and 9.58.
Tweenvest scores Cloudbreak Pharma Inc. across four factors: quality 39/100, value 49/100. Its strongest factor is value.
2592 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $140.32M
- Revenue (TTM)
- $269.00K
- P/E
- —
- EPS
- -0.14
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$9.58
- 52-week low
- HK$0.90
- Avg volume (3M)
- —
- Shares outstanding
- 924.69M
- Employees
- 61
- Next earnings
- —
About Cloudbreak Pharma Inc.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
- ISIN
- KYG2215S1084
- Founded
- 2015
- Listed since
- Jul 2, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
| Atrium Therapeutics, Inc.NasdaqGS: RNA | $143.69M | $8.21 | -2.26% |
| UnicoCell Biomed Co., Ltd.TWSE: 6794 | $142.50M | NT$71.60 | -9.25% |
| Outlook Therapeutics, Inc.NasdaqCM: OTLK | $142.44M | $0.59 | +0.24% |
| Anavex Life Sciences Corp.NasdaqGS: AVXL | $139.97M | $1.51 | +1.34% |
| Voyager Therapeutics, Inc.NasdaqGS: VYGR | $139.87M | $2.27 | -7.35% |
| 3billion, Inc.KOSDAQ: A394800 | $139.66M | ₩5,900.00 | -2.32% |
| NeoImmuneTech, Inc.KOSDAQ: A950220 | $139.14M | ₩1,892.00 | -4.69% |
Figures last refreshed Oct 11, 2026.